TARS
Tarsus Pharmaceuticals Inc
NASDAQ: TARS · HEALTHCARE · BIOTECHNOLOGY
$60.67
-2.29% today
Updated 2026-04-29
Market cap
$2.61B
P/E ratio
—
P/S ratio
5.78x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$39 – $85
Volume
0.6M
Tarsus Pharmaceuticals Inc (TARS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-14.70%
Operating margin
-5.26%
ROE
-23.40%
ROA
-9.45%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $0.00 | $-1.32M | — | — | — |
| 2019 | $0.00 | $-4.67M | — | — | — |
| 2020 | $33.43M | $-26.81M | -0.74% | -80.71% | -80.20% |
| 2021 | $57.03M | $-13.83M | 96.36% | -21.32% | -24.25% |
| 2022 | $25.82M | $-62.09M | 96.30% | -242.92% | -240.51% |
| 2023 | $17.45M | $-135.89M | 90.87% | -820.53% | -778.89% |
| 2024 | $182.95M | $-115.55M | 92.99% | -65.90% | -63.16% |
| 2025 | $451.36M | $-66.42M | 93.20% | -15.72% | -14.72% |